The US Food and Drug Administration (FDA) is warning the American public that a weight-loss drug may increase the risk of cancer.
In a statement on Tuesday, the FDA said a clinical trial had shown that those on a he prescription medication Belviq, also known in its generic form as lorcaserin, may face higher cancer risks than the general population does.
The trial was meant to evaluate whether the drug was safe to take for obese patients who were at risk of heart disease but, at the end of the study period, more participants had tumors after taking Belviq than a placebo.